Skip to main content
SpringerLink
Log in

Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis

  • Correspondence
  • Published:
Applied Health Economics and Health Policy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dranitsaris G, Mehta S. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Appl Health Econ Health Policy 2009; 7(1): 43–59

    Article  PubMed  Google Scholar 

  2. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010–9

    Article  PubMed  Google Scholar 

  3. Olschewski H, Galiè N, Kramer M, et al. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study [abstract]. 102nd International Conference of the American Thoracic Society; 2006 May 19–24; San Diego (CA)

    Google Scholar 

  4. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001; 358: 1119–23

    Article  PubMed  CAS  Google Scholar 

  5. Rubin L, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903

    Article  PubMed  CAS  Google Scholar 

  6. Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patient with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006; 114: 48–54

    Article  PubMed  Google Scholar 

  7. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441–7

    Article  PubMed  Google Scholar 

  8. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049–56

    Article  PubMed  CAS  Google Scholar 

  9. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–57

    Article  PubMed  Google Scholar 

  10. Lewis GD, Shah R, Shahzad K, et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007; 116: 1555–62

    Article  PubMed  CAS  Google Scholar 

  11. Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54(1 Suppl.): S78–84

    Article  PubMed  CAS  Google Scholar 

  12. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009 Oct; 30 (20): 2493–537

    Google Scholar 

  13. Garin MC, Clark L, Chumney EC, et al. Cost-utility of treatments for pulmonary arterial hypertension: a Markov state-transition decision analysis model. Clin Drug Investig 2009; 29(10): 635–46

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Marie-Claude Lefebvre is an employee of Actelion Pharmaceuticals Canada Inc., Canada. Elke Hunsche is an employee Actelion Pharmaceuticals Ltd, Switzerland.

Author information

Authors and Affiliations

  1. Medical Affairs, Actelion Pharmaceuticals Canada Inc., Quebec, Canada

    Marie-Claude Lefebvre

  2. Health Economics & Pricing, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

    Elke Hunsche

Authors
  1. Marie-Claude Lefebvre
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elke Hunsche
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lefebvre, MC., Hunsche, E. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Appl Health Econ Health Policy 8, 69–71 (2010). https://doi.org/10.1007/BF03256167

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256167

Keywords

Search

Navigation